Q-omics provides the consensus-scored RPL18AP15 profile across patient tissues and cancer cell-line models. RPL18AP15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPL18AP15 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL18AP15 RNA expression shows 6,257 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CHOL, COAD, and DLBC as cancer lineages where RPL18AP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18AP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18AP15 survival associations across molecular data types. RPL18AP15 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18AP15 RNA expression–survival associations across cancer types. High RPL18AP15 expression shows unfavorable associations in OV and KICH, but favorable associations in CHOL, BLCA, CESC and UVM. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify CHOL as the clearest survival context for RPL18AP15 RNA expression.
This table summarizes RPL18AP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL18AP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18AP15 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, KIRC and LUSC. The COAD box plot shows higher RPL18AP15 RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p = .002).
This table shows molecular features associated with RPL18AP15 in patient tissues and cancer cell lines. In patient samples, RPL18AP15 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
